gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HRMYHealthcarePharmaceuticals

Harmony Biosciences Holdings, Inc. Common Stock (HRMY)

$34.42−7.04%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$37.86▲ 29.08% in range
Nov 3, 2025Low $26.54 · High $42.86Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Harmony Biosciences Holdings closed at $34.41 on Nov 4, down 7.04%, 19.7% below its 52-week closing high. Volume of 2.4M shares was 2.24× its 20-day average (well above normal).

Split-adjusted performance: -12.6% over one month, +5.0% over six months, +17.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $261.28M, up 30.3% from a year earlier, with a net margin of 28.9%.

Short interest was 5.4M shares at the Oct 15 settlement, down 2.2% from the prior report (11.8% of float, 6.2 days to cover).

Market cap$2.00B58.2M shares
Revenue · quarter$261.3M+30.3% YoY
Diluted EPS$1.28+88.2% YoY
P/E · TTM11.1×P/S 2.1×
Net margin28.9%Gross 75.8%
Dividend yieldNone
52-week range26.54 – 42.86−19.7% from high
Volume2.4M2.24× 20-day avg
Volatility · 60d35.9%Annualised
Short % of float11.8%6.2 days to cover
Net cash$513.8MCash $667.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −10.6%1M −12.6%3M −11.2%6M +5.0%YTD −8.0%1Y +17.3%3Y +74.6%5Y −15.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum75
Revenue growth71
Net margin89
Value (low P/E)67
Size81

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.4M−2.2% vs prior
Days to cover6.2Settled Oct 15
% of float11.8%
Short vol. 10d76.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HRMYHarmony Biosciences Holdings$34.42−7.04%+5.0%+30.3%28.9%11.1$2.00B
SRPTSarepta Therapeutics,$18.99+2.43%−17.5%−34.3%−1.2%—$2.01BCompare
TRVITrevi Therapeutics$13.99+0.90%−1.9%———$1.99BCompare
TRAXFirst Tracks Biotherapeutics$49.04+5.83%————$2.06BCompare
XERSXeris Biopharma Holdings$10.46+1.06%+64.2%+28.7%−33.8%—$1.91BCompare
SDGRSchrodinger$28.52+4.93%+119.7%+7.5%10.1%—$2.13BCompare
AGIOAgios Pharmaceuticals$31.38+0.58%+16.3%+259.3%−225.1%—$1.87BCompare
ZBIOZenas BioPharma$28.46+0.28%+36.6%—−11145.6%—$1.85BCompare
SLSSELLAS Life Sciences Group$9.14+3.04%+77.5%———$1.85BCompare

News about Harmony Biosciences Holdings

All news →
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research · Oct 28, 2026NeutralHRMY or ARGX: Which Is the Better Value Stock Right Now?Zacks Investment Research · Oct 22, 2026▲ PositiveHRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?Zacks Investment Research · Oct 16, 2026▲ PositiveWhy Harmony Biosciences Stock Got Mashed on MondayThe Motley Fool · Oct 12, 2026▼ NegativeHarmony Biosciences Announces Planned CEO Transition to Support Next Phase of GrowthGlobeNewswire Inc. · Oct 12, 2026▲ Positive

Quick answers

What does Harmony Biosciences Holdings do?
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases.
What is HRMY's market cap?
$2B, based on the Nov 4 close of $34.41.
What is HRMY's P/E ratio?
11.1× trailing-twelve-month earnings of $181.27M.
Does Harmony Biosciences Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HRMY is sold short?
5.4M shares, 11.8% of float, as of Oct 15, 2026.
What sector is HRMY in?
Healthcare, in the Pharmaceuticals industry.

About Harmony Biosciences Holdings

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

HQ: Plymouth Meeting, PA293 employeesListed Aug 19, 2020harmonybiosciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology